Misonix, Inc. Retains Lytham Partners for Investor Relations

Contact: Robert Blum, Joe Dorame, Joe Diaz
Lytham Partners, LLC
602-889-9700
www.lythampartners.com

Farmingdale, NY - January 25, 2012 - Misonix, Inc. (NasdaqGM: MSON), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical applications, announced today the retention of Lytham Partners, LLC to conduct a national investor relations program.

Michael A. McManus, Jr., President and Chief Executive Officer of Misonix, commented, "Misonix has taken some very important steps over the last two years to streamline its business and to focus on its core competencies in the therapeutic ultrasonic medical device market. This renewed focus on our recurring revenue generating BoneScalpel™, SonicOne®, and SonaStar® systems should position Misonix for expanded growth and profitability into the future. We operate in large markets that approach $3 billion worldwide and are now focused on aggressively marketing our leading-edge products that we believe can produce improved patient outcomes and cost efficiencies. We have in place a combination of both direct and regional distributors throughout Europe, Eastern Europe, Middle East, India, South Africa, Australia, New Zealand, Latin America, as well as here in the U.S."

"We have retained Lytham Partners to help us reintroduce and appropriately position Misonix within the professional investment community," continued Mr. McManus. "We believe Lytham Partners is uniquely qualified to assist us in charting a course that will reward our loyal shareholders as we move to execute our strategic business plan. We look forward to a very successful collaboration."

Joseph Diaz, managing partner at Lytham Partners, said, "We are pleased to be working with Misonix. Mike McManus and his team have repositioned this company to focus on developing and marketing innovative ultrasonic medical device technology, including high value disposables from their extensive patent portfolio. The financial underpinnings of the company are strong with cash exceeding $6 million and zero long-term debt. In the course of our financial and strategic review, we became convinced that Misonix is a compelling company with significant potential, particularly after sitting in on demonstrations of their 'disruptive' technology, which provides for fast, effective and safe procedures. We are excited about the Company's prospects and its new execution strategy. We believe this is a company with great opportunities ahead."

About Lytham Partners

Lytham Partners, LLC provides expertise and guidance to mid- and small-cap companies in the healthcare, technology, services, agricultural, industrial, aerospace and defense segments, as well as the consumer and capital goods industries. The firm is dedicated to generating substantive communications programs with an emphasis on developing management credibility via data, clear articulation of achievable strategic plans, and timely interaction with investors. For more information visit our website at www.lythampartners.com.

About Misonix, Inc.

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

###